bioRxiv
Stem-cell mutations predicted blood cancer relapse after transplant
Relapse was reported in 95.7% of patients with detected stem-cell mutations versus 30.3% without them in an observational cohort after transplantation.Relapse was reported in 95.7% of patients with detected stem-cell mutations versus 30.3% without them in an observational cohort after transplantation.
Preprint: cohort studyBiomarkers
Who was studiedPeople with myelodysplastic neoplasms after donor transplantation
What changedRelapse occurred in 95.7% of patients with detected stem-cell mutations versus 30.3% without them
The catchThe study did not measure whether acting on mutation detection prevents relapse